VAL-083 NEW
| Price | $48 | $109 | $148 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-06 |
Product Details
| Product Name: VAL-083 | CAS No.: 23261-20-3 |
| Purity: ≥98% | Supply Ability: 10g |
| Release date: 2024/11/06 |
Product Introduction
Bioactivity
| 名稱(chēng) | VAL-083 |
| 描述 | VAL-083 is an alkylating agent with antitumor activity that produces N7 methylation on DNA. |
| 體外活性 | VAL-083 inhibits T98G cell growth in a dose-dependent manner (IC50 <5 μM). VAL-083 inhibits the proliferation of HUVEC and U251 cells at doses of more than 12.5 μg/mL. VAL-083 suppresses U251 and SF188 cell growth and induces apoptosis after 72 h. VAL-083 (5 μM) inhibits the growth of SF188 by ～95%. VAL-083 (3.125, 6.25, 12.5 μg/mL) also suppresses the migration and invasion and reduces MMP2, VEGF, VEGFR2, and FGF2 expression in HUVEC and U251 cells. VAL-083 (1, 2, 5 μM) dose-dependently induces cell cycle arrest at the G2/M phase in the 3 glioma cell lines. VAL-083 activates two parallel signaling cascades, the p53-p21, and the CDC25C-CDK1 cascade. VAL-083 significantly enhances the radiosensitivity of LN229 cells [1][2][3]. |
| 體內(nèi)活性 | VAL-083 significantly decreases the expression of VEGF, VEGFR2, and FGF2 at a concentration of 25 μg/mL, while at 50 μg/mL, it also reduces FGFR2 expression. Its action involves the activation of the CDC25C-CDK1 cascade in xenografted tumor models. Additionally, VAL-083 exhibits a dose-dependent inhibition of angiogenesis in zebrafish models at concentrations of 25, 50, and 100 μg/mL. In a murine study, VAL-083, administered intravenously at 5 mg/kg twice weekly for six weeks, markedly suppresses LN229 cell growth, resulting in a relative tumor growth rate (T/C) of 22.38% and a tumor growth inhibitory rate (TGI) of 83.58%. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : 40 mg/mL (273.71 mM), Sonication is recommended. DMF : 90 mg/mL (615.85 mM) |
| 關(guān)鍵字 | VAL083 | VAL-083 | VAL 083 | Inhibitor | DNA Alkylator/Crosslinker | inhibit |
| 相關(guān)產(chǎn)品 | Cyclophosphamide hydrate | Bendamustine hydrochloride | Busulfan | N-Nitroso-N-methylurea | Ifosfamide | Oxaliplatin | Streptozocin | Temozolomide | Methyl methanesulfonate | Cyclophosphamide | Carboplatin | Cisplatin |
| 相關(guān)庫(kù) | FDA上市及藥典收錄分子庫(kù) | 經(jīng)典已知活性庫(kù) | 上市藥物庫(kù) | ReFRAME 相關(guān)化合物庫(kù) | 酪氨酸激酶分子庫(kù) | 抗衰老化合物庫(kù) | 已知活性化合物庫(kù) | 共價(jià)抑制劑庫(kù) | 臨床前化合物庫(kù) | 人代謝物化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-31 | |
| $0.00/1kg |
VIP2Y
|
Sichuan HongRi Pharma-Tech Co.,Ltd
|
2024-04-10 | |
| $10.00/1g |
Shijiazhuang Saixin Technology Co., Ltd.
|
2023-09-12 | ||
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-07-05 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY